Figure 1 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

2026 Open access

Read full text
Authors: Robert L. Hollis, Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William Rodgers, David W. M. Millan, Karen Carty, Robert Louis Coleman, Kathleen N. Moore, Angeles Alvarez Secord, David M. O’Malley, John K. Chan
+13 more Andrea R. Hagemann, Stephanie L. Gaillard, Saketh R. Guntupalli, Mitchell I. Edelson, Peter Graham Rose, Oliver Dorigo, Susana N. Banerjee, Ailith Ewing, Michael Churchman, Anil K. Sood, C. Simon Herrington, Charlie Gourley, David Marc Gershenson
DOI: 10.1158/1078-0432.31353253
Cited by: 0

Abstract

Study case flow diagram for WES of translational specimens from patients enrolled in GOG281. One hundred thirty-four samples underwent successful WES, of which 112 were also evaluable for pERK via IHC. Additionally, 36 samples were evaluable for pERK IHC that did not have matching WES.

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer Ovarian function and disorders

Publication details

Publication date
17 February 2026
Language
EN